









Markets
/
Stocks
/
nasdaq-bon
/

Bon Natural Life Ltd

BON

1.910USD

-0.030-1.55%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

7.02MMarket Cap

--P/E TTM



Bon Natural Life Ltd

1.910

-0.030-1.55%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Bon Natural Life Ltd

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is high. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Bon Natural Life Ltd's Score

Industry at a Glance

Industry Ranking

139 / 173

Overall Ranking

598 / 4682

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Bon Natural Life Ltd Highlights

StrengthsRisks

Bon Natural Life Ltd is a China-based company principally engaged in the manufacturing and sales of personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers, natural health supplements, such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements. The Company's product categories include fragrance compounds, health supplements (natural, functional active ingredients for powder drinks) and bioactive food ingredients. Fragrance compounds product category includes clary sage extract products. Bioactive food ingredients include stachyose, milk thistle extracts, apple extracts, phloretin and pomegranate extract products. The Company’s products are applied in the functional food, personal care, cosmetic and pharmaceutical industries.

Growing

The company is in a growing phase, with the latest annual income totaling USD 23.84M.

Fairly Valued

The company’s latest PE is 0.46, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 29.46K shares, increasing 47.34% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Pharmaceuticals industry's average is 7.77. Its latest quarterly revenue reached 13.66M, representing a year-over-year decrease of 11.13%, while its net profit experienced a year-over-year decrease of 83.50%.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Bon Natural Life Ltd's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 7.34, which is higher than the Pharmaceuticals industry's average of 7.19. Its current P/E ratio is 0.46, which is 6097.50% below the recent high of 28.55 and 97.29% above the recent low of 0.01.

Score

Industry at a Glance

Previous score

7.34

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 139/173

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

There is no earnings forecast score for this company; the Pharmaceuticals industry's average is 7.78.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 3.27, which is lower than the Pharmaceuticals industry's average of 7.05. Sideways: Currently, the stock price is trading between the resistance level at 2.24 and the support level at 1.70, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.45

Change

-0.18

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.055

Neutral

RSI(14)

50.611

Neutral

STOCH(KDJ)(9,3,3)

34.731

Buy

ATR(14)

0.144

High Vlolatility

CCI(14)

-39.833

Neutral

Williams %R

63.325

Sell

TRIX(12,20)

-0.159

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

1.872

Buy

MA10

1.899

Buy

MA20

1.997

Sell

MA50

1.876

Buy

MA100

1.632

Buy

MA200

1.219

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 5.00, which is lower than the Pharmaceuticals industry's average of 5.59. The latest institutional shareholding proportion is 0.73%, representing a quarter-over-quarter increase of 1252.04%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

HRT Financial LP

15.34K

UBS Financial Services, Inc.

12.92K

Tower Research Capital LLC

1.20K

Hawthorn Fruit, Ltd.

548.00

Chen (Wenjuan)

80.00

Raymond James Financial Services Advisors, Inc.

1.00

Ground Swell Capital, LLC

-100.00%

Renaissance Technologies LLC

Star Investors

-100.00%

Hu (Yongwei)

-100.00%

SBI Securities Co., Ltd.

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Pharmaceuticals industry's average is 5.11. The company's beta value is -0.36. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.